Clinical Trial Update: A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma [Phase 1]

View source ↗

Summary

This Phase 1 trial of LY2940680 in pediatric medulloblastoma and rhabdomyosarcoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma
• Rhabdomyosarcoma

Drugs mentioned

• LY2940680 (LY2940680)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Medulloblastoma, Childhood, Rhabdomyosarcoma | Phase 1 | Status: WITHDRAWN